Premal Thaker

Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2)

Emily Ko, Nikita Bisht, Bradley Corr, Steven Friedman et autres

OBJECTIVE: Mismatch repair deficiency (dMMR), high microsatellite instability (MSI-H), and high tumor mutation burden (TMB-H) are predictive and prognostic biomarkers in endometrial cancer. We aimed to characterize the racial/ethnic distribution of molecular markers and the clinical characteristics among endometrial cancer patients with …

us (code pays fourni par la source)

Abstract B058: IMNN-001, a novel immune-oncology therapeutic delivering IL-12 to ovarian tumor and its microenvironment, facilitating immune reprogramming and survival benefit in the clinic

Khursheed Anwer, Subeena Sood, Premal Thaker, William Bradley et autres

Abstract IL-12 development as an anticancer agent over the last decades has been curtailed by the highly toxic adverse events resulting from systemic administration, including organ damage and shock; to overcome this, we have developed IMNN-001, a novel, non-viral immune-oncology product, to …

us (code pays fourni par la source)

Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study

Angela Nolin, Morgan Brown, Samantha Thomas, Kyle C. Strickland et autres

us (code pays fourni par la source)

Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201

Rachel Grisham, Els Van Nieuwenhuysen, Alessandro Santin, Véronique D'Hondt et autres

us, be, fr, gb, es, it (code pays fourni par la source)

Treatment-induced changes in FRα expression in ovarian cancer cell models and associated sensitivity to Mirvetuximab Soravtansine

Mostafa Eyada, Kevin Rodriguez, Prasanth Thuthika, Megan Loeb et autres

us (code pays fourni par la source)

Comparing intrathecal morphine with intraoperative lidocaine infusion to epidural anesthesia with postoperative PCA for patients undergoing exploratory laparotomy: A randomized controlled trial

AT Cohen, Michael Toboni, Dong Wang, Lara W. Crock et autres

us (code pays fourni par la source)

Safety and early translational report of a phase I study of PD-1 inhibition with dostarlimab in addition to standard of care definitive radiation for inoperable endometrial cancer

Rachel Furuya, Liyun Chen, Linda Odibo, Lulu Sun et autres

us (code pays fourni par la source)

BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers

Jae-Weon Kim, Domenica Lorusso, Bradley Monk, Jeong-Yeol Park et autres

kr, us, it, fr, be, es, de, pl (code pays fourni par la source)

Results of a randomized phase III trial of letrozole alone versus paclitaxel and carboplatin followed by letrozole as initial treatment for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal low-grade serous carcinoma (NRG-GY019, NCT04095364)

Amanda Fader, Austin Miller, Lilian Gien, Amy Deery et autres

us, ca, kr, ge (code pays fourni par la source)

Correlation of patient reported outcomes and physical exam screening for pelvic floor dysfunction: An opportunity for improved QoL during chemoradiotherapy for cervical cancer

Premal Thaker, Sarah Badwan, Tyler McKinnish, Stephanie Markovina et autres

us (code pays fourni par la source)

Embedding precision medicine into gynecologic cancer care: lessons from a nationwide quality improvement effort

Bianca Alvarez, Kari Hacker, Russell Broaddus, Premal Thaker et autres

us (code pays fourni par la source)

Real-world safety profile and clinical management of patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib therapy: Final results from the 1NSPIRE chart review study

Lisa Landrum, Premal Thaker, Tirza Areli Calderón Boyle, Jonathan Lim et autres

us, ca (code pays fourni par la source)